Neurocrine Biosciences (NBIX) Q1 2026: Ingreza Drives 44% Growth as Chronicity Annualizes Above $600M

May 5, 2026 | By EarningsIQ Research

Neurocrine Biosciences delivered a step-change quarter with net product sales up 44% year-over-year, driven by robust Ingreza growth and Chronicity’s rapid ramp to blockbuster potential. The company reaffirmed full-year guidance and highlighted an expanding pipeline, while signaling that its commercial and R&D engines are firing in parallel. With a pending portfolio-expanding acquisition and multiple late-stage readouts ahead, Neurocrine is positioned for multi-year visibility and optionality.

Summary

• Ingreza Momentum Surges: Double-digit patient growth and new starts lift the flagship neurology franchise.
• Chronicity Launch Outpaces Expectations: Broad adoption and high persistency push annual sales above $600 million.
• Pipeline and M&A Set Up 2027 Catalysts: Multiple Phase III readouts and the Celeno acquisition expand future optionality.

Business Overview

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing therapies for neurological, psychiatric, endocrine, and rare disorders. The company generates revenue primarily through net product sales of its leading drugs: Ingreza, a VMAT2 inhibitor for tardive dyskinesia (TD) and Huntington’s chorea, and Chronicity, a therapy for classic congenital adrenal hyperplasia (CAH). Additional growth is expected from pipeline assets and the anticipated addition of ICAT-XR through the Celeno Therapeutics acquisition.

Performance Analysis

Q1 2026 marked a record quarter for Neurocrine, with net product sales exceeding $800 million for the first time—reflecting 44% year-over-year growth. Ingreza, now nine years post-launch, delivered $657 million in sales, up 20% YoY, fueled by double-digit volume growth and record new patient additions. Chronicity, in its fifth quarter post-launch, contributed $153 million and is annualizing above $600 million, supported by strong persistency and balanced adoption across prescriber segments.

Underlying demand, not inventory effects, drove the quarter, with management calling out a “clean” performance. Both products benefited from favorable reimbursement and broadening prescriber bases, while the company’s operating leverage enabled approximately $200 million in net income (GAAP and non-GAAP). Notably, Neurocrine continues to invest in R&D and commercial expansion, with full impact of these investments expected to show in Q2 and beyond.

• Prescription Accumulation Drives Growth: Most prescribers of Chronicity have treated only one patient so far, indicating substantial untapped opportunity.
• Minimal Seasonality for Chronicity: Unlike Ingreza, Chronicity’s payer mix limits Q1 disruption, supporting steady quarter-to-quarter growth.
• Cash Flow Enables Pipeline Investment: Durable commercial assets are funding an expanded R&D agenda and business development.

With both commercial and pipeline momentum, Neurocrine is positioned for continued top-line expansion and margin leverage as the year progresses.

Executive Commentary

Strategic Positioning

1. Ingreza: Market Penetration and Durability

Ingreza remains Neurocrine’s core growth engine, with only 10% of the estimated 800,000 U.S. TD patients currently treated with a VMAT2 inhibitor. Management highlighted that ongoing investments in sales force and awareness initiatives are expanding reach, and consensus screening recommendations are expected to further drive market penetration, particularly in long-term care settings.

2. Chronicity: Early Ramp and Broad Adoption

Chronicity’s launch trajectory is ahead of internal expectations, with high persistency and balanced adoption across pediatric and adult endocrinology segments. Prescriber depth remains shallow—most have treated only one patient—implying significant runway. The expanded sales force and continued provider education are positioned to accelerate both breadth and depth of prescribing.

3. Pipeline Expansion and Portfolio Diversification

Neurocrine’s R&D engine is advancing six new Phase I and four new Phase II programs in 2026, spanning neurology, psychiatry, endocrinology, and immunology. Key near-term catalysts include Phase III readouts for Ossipapitor in major depressive disorder and DirectLadeen in schizophrenia in 2027. The company is also moving into gene therapy and combination obesity programs, aiming for first-in-human studies this year.

4. Business Development and M&A

The pending acquisition of Celeno Therapeutics and ICAT-XR strengthens the commercial portfolio and positions the company for continued revenue diversification. Integration planning is underway, with management emphasizing a seamless transition and focus on Prader-Willi syndrome patients. No financial guidance on the deal is provided yet, but details are expected post-close in Q2.

5. Commercial Execution and Capital Allocation

Strong cash flows from Ingreza and Chronicity support continued investment in pipeline and business development, consistent with management’s capital allocation framework. The company is balancing commercial expansion, innovation, and opportunistic M&A to drive long-term shareholder value.

Key Considerations

This quarter demonstrates Neurocrine’s ability to scale its commercial franchises while simultaneously investing in pipeline innovation and external growth. The company’s strategic levers are aligned to capture both near-term and long-term value creation.

Key Considerations:

• Prescriber Depth Remains Early: Most Chronicity prescribers have only treated one patient, providing significant expansion headroom as awareness and experience build.
• Pipeline Readouts Will Shape 2027 and Beyond: Multiple late-stage clinical milestones and new modalities (gene therapy, peptide agonists) could materially alter the company’s growth trajectory.
• Sales Force Expansion as a Growth Catalyst: Increased field presence is expected to drive both Ingreza and Chronicity adoption in the back half of 2026.
• M&A Optionality Adds Diversification: The Celeno deal and future business development are set to broaden the portfolio and reduce single-product risk.

Risks

Key risks include potential delays or setbacks in late-stage pipeline programs, integration risk from the Celeno acquisition, and slower-than-expected adoption of Chronicity as prescriber depth builds. Competitive dynamics in VMAT2 inhibitors and payer coverage changes could also pressure Ingreza’s growth. Macro headwinds or regulatory changes in pricing and reimbursement remain ongoing sector risks.

Forward Outlook

For Q2 2026, Neurocrine expects:

• Continued strong momentum for both Ingreza and Chronicity, with full impact of commercial expansion flowing through financials
• Initial integration of Celeno Therapeutics, with financial guidance to be provided post-close

For full-year 2026, management reaffirmed guidance:

• Ingreza net sales of $2.7 to $2.8 billion

Management highlighted several factors that will shape the outlook:

• Expanded sales force and awareness campaigns to drive new patient starts
• Multiple Phase I and Phase II program initiations and key data updates at upcoming scientific meetings

Takeaways

Neurocrine’s Q1 results showcase robust commercial execution and a deepening pipeline, positioning the company for continued growth and strategic flexibility.

• Commercial Engines Deliver: Ingreza’s durable growth and Chronicity’s rapid ramp are funding both R&D and M&A, creating a virtuous cycle for future expansion.
• Pipeline and Portfolio Optionality: Multiple late-stage readouts and the Celeno acquisition expand the company’s addressable market and reduce reliance on legacy assets.
• Watch for Depth of Prescriber Penetration: The pace at which prescribers move beyond initial patients will be a key determinant of Chronicity’s long-term trajectory.

Conclusion

Neurocrine delivered a breakout quarter, underpinned by strong commercial performance and pipeline progress. The company’s ability to execute on multiple fronts—commercial, R&D, and M&A—sets up a compelling multi-year growth story, but execution on prescriber expansion and pipeline milestones will be critical to sustaining momentum.

Industry Read-Through

Neurocrine’s results provide a clear signal that focused commercial execution and targeted field force expansion can unlock significant growth even in mature neurology markets. The Chronicity launch demonstrates that rare disease franchises can achieve blockbuster status with high persistency and payer access, while the company’s pipeline breadth highlights the increasing importance of therapeutic diversification in biopharma. Competitors in VMAT2 inhibition, CAH, and emerging obesity therapeutics should monitor Neurocrine’s commercial and R&D playbook, as the company’s success in activating prescribers and investing in next-generation assets may set a new bar for commercial and pipeline execution in specialty pharma.

NBIX Healthcare Biotechnology Neurology Rare Disease Pipeline Commercialization M&A